Tislelizumab, a humanized IgG4 variant monoclonal antibody targeting programmed cell death protein 1 (PD-1) with exceptional specificity, has shown higher affinity for PD-1 and a slower dissociation rate than pembrolizumab, which could theoretically improve efficacy.12 Notably, tislelizumab plus chemotherapy has been reported to improve survival as a first-line treatment for esophageal squamous cell carcinoma (ESCC) and metastatic nasopharyngeal cancer.13,14 However, few studies on its use in neoadjuvant therapy of TNBC have been reported. Here, PDCD1 is linked to esophageal squamous cell carcinoma.